1. Home
  2. NTHI vs SMTI Comparison

NTHI vs SMTI Comparison

Compare NTHI & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$11.08

Market Cap

221.5M

Sector

Health Care

ML Signal

HOLD

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$19.50

Market Cap

178.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTHI
SMTI
Founded
2008
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.5M
178.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NTHI
SMTI
Price
$11.08
$19.50
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$41.00
AVG Volume (30 Days)
71.2K
64.4K
Earning Date
02-23-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,990.00
$101,877,532.00
Revenue This Year
N/A
$21.60
Revenue Next Year
N/A
$16.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.52
52 Week Low
$3.20
$18.90
52 Week High
$25.00
$36.31

Technical Indicators

Market Signals
Indicator
NTHI
SMTI
Relative Strength Index (RSI) 64.35 34.77
Support Level $9.05 $20.12
Resistance Level $11.31 $20.20
Average True Range (ATR) 1.15 1.16
MACD 0.17 -0.16
Stochastic Oscillator 80.93 14.08

Price Performance

Historical Comparison
NTHI
SMTI

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Share on Social Networks: